United Therapeutics CORP Form 4 insider transactions

United Therapeutics CEO Martine Rothblatt executed pre-arranged stock option exercises and subsequent sales of common stock on October 1 and 2, 2025, under a 10b5-1 trading plan.

United Therapeutics EVP & General Counsel Paul A. Mahon exercised stock options and sold 11,000 shares as part of a pre-arranged 10b5-1 trading plan.

United Therapeutics Corp's President and COO, Michael Benkowitz, exercised stock options and sold 22,500 common shares on September 29, 2025, under a Rule 10b5-1 trading plan.

United Therapeutics Chairperson & CEO Martine Rothblatt executed pre-arranged stock option exercises and subsequent sales of common stock totaling 11,990 shares in late September 2025 under a Rule 10b5-1 trading plan.

United Therapeutics Corp's Chairperson and CEO, Martine A. Rothblatt, executed pre-arranged stock option exercises and subsequent sales of common stock on September 25 and 26, 2025.

United Therapeutics Director Christopher Causey exercised options and sold 1,000 shares.

United Therapeutics Chairperson & CEO Martine A. Rothblatt executed pre-arranged stock option exercises and subsequent sales of common stock in late September 2025 under a 10b5-1 trading plan.

United Therapeutics Corporation's President and COO, Michael Benkowitz, executed a pre-planned sale of 22,500 shares of common stock for over $9.3 million after exercising stock options.

United Therapeutics CEO Martine Rothblatt executed pre-arranged stock option exercises and sales totaling 8,000 shares of common stock.

United Therapeutics Director Judy D. Olian sold 1,800 shares of common stock for approximately $747,767 through a pre-arranged trading plan.

United Therapeutics EVP & General Counsel Paul A. Mahon exercised stock options and sold 11,000 shares of common stock under a pre-arranged 10b5-1 plan.

United Therapeutics CEO Martine Rothblatt executed pre-planned stock option exercises and subsequent sales of common stock on September 17 and 18, 2025, under a 10b5-1 trading plan.

United Therapeutics Corp's Chairperson & CEO, Martine A. Rothblatt, exercised and sold 4,000 common stock options on September 16, 2025, under a pre-arranged 10b5-1 trading plan.

United Therapeutics President and COO Michael Benkowitz executed pre-planned sales of common stock following option exercises on September 15, 2025.

United Therapeutics CEO Martine Rothblatt exercised stock options and sold a portion of the acquired shares under a pre-arranged 10b5-1 trading plan.

Martine Rothblatt, Chairperson and CEO of United Therapeutics, sold shares under a pre-arranged 10b5-1 trading plan.

United Therapeutics Corp's President and COO, Michael Benkowitz, exercised stock options and sold a portion of the resulting common stock through pre-arranged trading plans.

United Therapeutics Director Jan Malcolm sold 700 shares of common stock for $400.29 per share, reducing her direct beneficial ownership to 520 shares.

United Therapeutics CEO Martine Rothblatt exercised stock options and sold common stock as part of a pre-arranged 10b5-1 trading plan.

United Therapeutics Director Tommy G. Thompson exercised stock options and subsequently sold 4,560 shares of common stock on September 10, 2025.

Paul A. Mahon, EVP & General Counsel of United Therapeutics, exercised stock options and sold 11,000 shares of common stock under a pre-arranged 10b5-1 plan.

United Therapeutics' President and COO, Michael Benkowitz, executed pre-planned sales of common stock totaling 22,500 shares after exercising stock options, alongside an additional disposal of 2,648 shares.

United Therapeutics Director Christopher Causey exercised stock options and sold 3,000 shares of common stock under a pre-arranged 10b5-1 plan.

United Therapeutics' EVP & General Counsel, Paul A. Mahon, exercised stock options and subsequently sold 11,000 shares of common stock under a pre-arranged 10b5-1 plan.

United Therapeutics EVP & General Counsel Paul A. Mahon exercised stock options and sold 11,000 shares for approximately $3.3 million under a pre-arranged 10b5-1 plan.

United Therapeutics Director Tommy G Thompson received an annual award of 3,650 stock options with an exercise price of $306.41.

United Therapeutics director Christopher Patusky reported the vesting of restricted stock units and the acquisition of new equity awards.

United Therapeutics Director Judy D. Olian reported the vesting of 1,190 restricted stock units into common stock and the grant of 1,310 new restricted stock units.

United Therapeutics Director Nilda Mesa reported the vesting of restricted stock units and new equity awards, including stock options and additional restricted stock units.

United Therapeutics director Linda Maxwell was granted 3,650 stock options as part of an annual non-employee director award.